{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:40:34Z","timestamp":1793580034520,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2873"],"award-info":[{"award-number":["GRK2873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2873"],"award-info":[{"award-number":["GRK2873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>PARP inhibitors (PARPi) are approved for the treatment of platinum-based therapy-responsive ovarian cancer. However, this severely restricts their therapeutic potential, since there is only limited knowledge on the efficacy of PARPi in platinum drug-resistant ovarian cancer cells. Here, we studied three approved PARPi, niraparib, olaparib, and rucaparib in three ovarian cancer cell lines and their cisplatin-resistant sublines. Complex response profiles demonstrated that cisplatin resistance was not consistently associated with cross-resistance to PARPi. The combination of PARPi with inhibitors of relevant DNA damage response kinases which are potentially involved in PARPi resistance, such as ATR, ATM, CHK1, and WEE1 again resulted in complex activity patterns, but also identified ATR and ATM as the most promising targets for increasing PARPi activity. Cell adhesion-mediated resistance via collagen I is known to mediate cisplatin resistance. Here, we show that collagen I can also mediate PARPi resistance, which can also be tackled by ATR and ATM inhibition in cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. In conclusion, our findings revealed complex, cell line-specific PARPi response profiles. This complexity is in line with other studies investigating drug-resistant cancer cell lines and with the complex evolutionary processes in tumors from cancer patients. Notably, cisplatin resistance was not directly correlated with PARPi resistance, and ATM and ATR inhibitors can increase PARPi activity against cisplatin-sensitive and -resistant ovarian cancer cells. Moreover, we demonstrated for the first time that cell adhesion-mediated resistance can contribute to PARPi resistance, which can also be alleviated by ATR and ATM.<\/jats:p>","DOI":"10.1038\/s41420-025-02740-1","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:53:00Z","timestamp":1759762380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition"],"prefix":"10.1038","volume":"11","author":[{"given":"Philipp","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Bade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Maria","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Skalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-5888","authenticated-orcid":false,"given":"Martin","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-7201","authenticated-orcid":false,"given":"Gerd","family":"Bendas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2740_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/bjc.2016.67","volume":"114","author":"JS Brown","year":"2016","unstructured":"Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J. Cancer. 2016;114:713\u20135. https:\/\/doi.org\/10.1038\/bjc.2016.67.","journal-title":"Br J. Cancer"},{"key":"2740_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev. Drug Discov. 2020;19:711\u201336. https:\/\/doi.org\/10.1038\/s41573-020-0076-6.","journal-title":"Nat Rev. Drug Discov"},{"key":"2740_CR3","doi-asserted-by":"publisher","unstructured":"Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, et al. A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA: A Cancer Journal for Clinicians https:\/\/doi.org\/10.3322\/caac.21870 (2025).","DOI":"10.3322\/caac.21870"},{"key":"2740_CR4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(14)70228-1.","journal-title":"Lancet Oncol"},{"key":"2740_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6.","journal-title":"Lancet"},{"key":"2740_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1611310.","journal-title":"N Engl J Med"},{"key":"2740_CR7","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun. 2022;33:100629 https:\/\/doi.org\/10.1016\/j.ctarc.2022.100629.","journal-title":"Cancer Treat Res Commun"},{"key":"2740_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/GO.20.00269","volume":"7","author":"A Agarwal","year":"2021","unstructured":"Agarwal A, Baghmar S, Dodagoudar C, Qureshi S, Khurana A, Vaibhav V, Kumar G. PARP inhibitor in platinum-resistant ovarian cancer: single-center real-world experience. JCO Glob. Oncol. 2021;7:506\u201311. https:\/\/doi.org\/10.1200\/GO.20.00269.","journal-title":"JCO Glob. Oncol"},{"key":"2740_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636\u201348.https:\/\/doi.org\/10.1016\/S1470-2045(19)30029-4.","journal-title":"Lancet Oncol"},{"key":"2740_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","volume":"130","author":"S Nicum","year":"2024","unstructured":"Nicum S, McGregor N, Austin R, Collins L, Dutton S, McNeish I, et al. Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. Br J Cancer. 2024;130:941\u201350. https:\/\/doi.org\/10.1038\/s41416-023-02567-6.","journal-title":"Br J Cancer"},{"key":"2740_CR11","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","volume":"40","author":"D Huang","year":"2021","unstructured":"Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40:6395\u2013405. https:\/\/doi.org\/10.1038\/s41388-021-02055-2.","journal-title":"Oncogene"},{"key":"2740_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semcancer.2020.10.016","volume":"77","author":"AABA Da Costa","year":"2021","unstructured":"Da Costa AABA, Baiocchi G. Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets. Seminars Cancer Biol. 2021;77:29\u201341. https:\/\/doi.org\/10.1016\/j.semcancer.2020.10.016.","journal-title":"Seminars Cancer Biol"},{"key":"2740_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. A new wave of innovations within the DNA damage response. Sig Transduct. Target Ther. 2023;8:338 https:\/\/doi.org\/10.1038\/s41392-023-01548-8.","journal-title":"Sig Transduct. Target Ther"},{"key":"2740_CR14","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression in bRCA-mutant ovarian cancer models. Clin Cancer Res. 2017;23:3097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2273.","journal-title":"Clin Cancer Res"},{"key":"2740_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2.","journal-title":"Nat Commun"},{"key":"2740_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","volume":"35","author":"Y Fang","year":"2019","unstructured":"Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell. 2019;35:851\u201367. https:\/\/doi.org\/10.1016\/j.ccell.2019.05.001.","journal-title":"Cancer Cell"},{"key":"2740_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev. Cancer. 2009;9:665\u201374. https:\/\/doi.org\/10.1038\/nrc2714.","journal-title":"Nat Rev. Cancer"},{"key":"2740_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/biom9120788","volume":"9","author":"K Wantoch von Rekowski","year":"2019","unstructured":"Wantoch von Rekowski K, K\u00f6nig P, Henze S, Schlesinger M, Zawierucha P, Januchowski R, Bendas G. The impact of integrin-mediated matrix adhesion on cisplatin resistance of W1 ovarian cancer cells. Biomolecules. 2019;9:788 https:\/\/doi.org\/10.3390\/biom9120788.","journal-title":"Biomolecules"},{"key":"2740_CR19","doi-asserted-by":"publisher","first-page":"19455","DOI":"10.1038\/s41598-019-55934-w","volume":"9","author":"D Naci","year":"2019","unstructured":"Naci D, Berrazouane S, Barab\u00e9 F, Aoudjit F. Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation. Sci Rep. 2019;9:19455 https:\/\/doi.org\/10.1038\/s41598-019-55934-w.","journal-title":"Sci Rep"},{"key":"2740_CR20","doi-asserted-by":"publisher","first-page":"113270","DOI":"10.1016\/j.celrep.2023.113270","volume":"42","author":"X Yang","year":"2023","unstructured":"Yang X, Chen X, Zhang S, Fan W, Zhong C, Liu T, et al. Collagen 1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer. Cell Rep. 2023;42:113270 https:\/\/doi.org\/10.1016\/j.celrep.2023.113270.","journal-title":"Cell Rep"},{"key":"2740_CR21","doi-asserted-by":"publisher","first-page":"167448","DOI":"10.1016\/j.bbadis.2024.167448","volume":"1870","author":"P K\u00f6nig","year":"2024","unstructured":"K\u00f6nig P, Eichhorn JM, Suparman E, B\u00fcckrei\u00df N, Cinatl J, Michaelis M, Bendas G. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167448 https:\/\/doi.org\/10.1016\/j.bbadis.2024.167448.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2740_CR22","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.celrep.2018.10.096","volume":"25","author":"E Papp","year":"2018","unstructured":"Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, No\u00eb M, et al. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell Rep. 2018;25:2617\u201333. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.096.","journal-title":"Cell Rep"},{"key":"2740_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10549-009-0639-z","volume":"122","author":"C Schroeder","year":"2010","unstructured":"Schroeder C, Stutzmann F, Weber BHF, Riess O, Bonin M. High-throughput resequencing in the diagnosis of BRCA1\/2 mutations using oligonucleotide resequencing microarrays. Breast Cancer Res Treat. 2010;122:287\u201397. https:\/\/doi.org\/10.1007\/s10549-009-0639-z.","journal-title":"Breast Cancer Res Treat"},{"key":"2740_CR24","doi-asserted-by":"publisher","first-page":"e61520","DOI":"10.1371\/journal.pone.0061520","volume":"8","author":"SJ Pettitt","year":"2013","unstructured":"Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, et al. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLOS One. 2013;8:e61520 https:\/\/doi.org\/10.1371\/journal.pone.0061520.","journal-title":"PLOS One"},{"key":"2740_CR25","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang S-YN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res"},{"key":"2740_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-380888-2.00003-0.","journal-title":"Adv Cancer Res"},{"key":"2740_CR27","doi-asserted-by":"publisher","first-page":"118663","DOI":"10.1016\/j.bbamcr.2020.118663","volume":"1867","author":"F Baltes","year":"2020","unstructured":"Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G. \u03b21-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res. 2020;1867:118663 https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118663.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2740_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23:66. https:\/\/doi.org\/10.1186\/s12943-024-01967-3.","journal-title":"Mol Cancer"},{"key":"2740_CR29","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/s41598-020-59074-4","volume":"10","author":"AA Antolin","year":"2020","unstructured":"Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep. 2020;10:2585 https:\/\/doi.org\/10.1038\/s41598-020-59074-4.","journal-title":"Sci Rep"},{"key":"2740_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nbt.2121","volume":"30","author":"E Wahlberg","year":"2012","unstructured":"Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell A-G, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30:283\u20138. https:\/\/doi.org\/10.1038\/nbt.2121.","journal-title":"Nat Biotechnol"},{"key":"2740_CR31","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1038\/cddis.2011.129","volume":"2","author":"M Michaelis","year":"2011","unstructured":"Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, L\u00f6schmann N, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2:e243.","journal-title":"Cell Death Dis"},{"key":"2740_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262\u20139. https:\/\/doi.org\/10.1038\/nm.4040.","journal-title":"Nat Med"},{"key":"2740_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13046-021-02093-4","volume":"40","author":"T Rothenburger","year":"2021","unstructured":"Rothenburger T, Thomas D, Schreiber Y, Wratil PR, Pflantz T, Knecht K, et al. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res. 2021;40:317 https:\/\/doi.org\/10.1186\/s13046-021-02093-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"2740_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/path.6034","volume":"259","author":"GA Pettitt","year":"2023","unstructured":"Pettitt GA, Hurst CD, Khan Z, McPherson HR, Dunning MC, Alder O, et al. Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro. J Pathol. 2023;259:220\u201332. https:\/\/doi.org\/10.1002\/path.6034.","journal-title":"J Pathol"},{"key":"2740_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616:553\u201362. https:\/\/doi.org\/10.1038\/s41586-023-05776-4.","journal-title":"Nature"},{"key":"2740_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023;616:525\u201333. https:\/\/doi.org\/10.1038\/s41586-023-05783-5.","journal-title":"Nature"},{"key":"2740_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","volume":"616","author":"C Mart\u00ednez-Ruiz","year":"2023","unstructured":"Mart\u00ednez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023;616:543\u201352. https:\/\/doi.org\/10.1038\/s41586-023-05706-4.","journal-title":"Nature"},{"key":"2740_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.biopha.2012.11.011","volume":"67","author":"R Januchowski","year":"2013","unstructured":"Januchowski R, Zawierucha P, Andrzejewska M, Ruci\u0144ski M, Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother. 2013;67:240\u20135. https:\/\/doi.org\/10.1016\/j.biopha.2012.11.011.","journal-title":"Biomed Pharmacother"},{"key":"2740_CR39","unstructured":"Industrial Biotechnology Centre. The Resistant Cancer Cell Line (RCCL) collection - Industrial Biotechnology Centre - Research at Kent. 23.06.2023. https:\/\/research.kent.ac.uk\/industrial-biotechnology-centre\/the-resistant-cancer-cell-line-rccl-collection\/. Accessed 8 Jan 2025."},{"key":"2740_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-023-04548-1","volume":"92","author":"P K\u00f6nig","year":"2023","unstructured":"K\u00f6nig P, Zhulenko R, Suparman E, Hoffmeister H, B\u00fcckrei\u00df N, Ott I, Bendas G. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis. Cancer Chemother Pharmacol. 2023;92:57\u201369. https:\/\/doi.org\/10.1007\/s00280-023-04548-1.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02740-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:53:01Z","timestamp":1759762381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02740-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2740"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02740-1","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Ethics approval was not needed, as this study does not involve animal or patient trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"438"}}